ClinicalTrials.gg
SuspendedNCT04094649Updated Aug 20, 2021

Acute Study of Effect of Ultrasound Vagus Nerve Stimulation on Glycemia

An interventional study of Ultrasound Vagus Nerve Stimulation (DECIMA) in Diabetes Mellitus, Type 2, sponsored by Aucta Technologies, Inc.. Suspended at 1 site in United States. Open to participants aged 21 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-08-20.

Sponsored by Aucta Technologies, Inc. · Not applicable, Interventional, and Device feasibility

Why this study was suspended
Pending funding
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Study summary

This is an early feasibility study to evaluate the proof of concept of modulation of glycemia by non-invasive ultrasound vagus nerve stimulation. This protocol is exploratory in nature, therefore it is not intended to capture statistically valid results or test statistical hypotheses. However, statistical analysis of the primary endpoint will be performed to allow more critical reflection of the data and to estimate the treatment effect for consider-ation in further studies.

Read the detailed description

The DECIMA device comprises an array of two focused ultra-sound applicators arranged with overlapping foci to deliver acoustic energy to a known focal depth within tissue. The focused ultrasound applicators are each comprised of an ultra-sound-emitting piezoelectric element coupled to a focusing lens. The array of the DECIMA device is coupled with an ultra-sound imaging system to locate the cervical vagus nerve, and a control system to deliver short bursts of ultrasound energy that are controlled by the operator in time and intensity.

The imaging system and the array of applicators are calibrated together, so the power is focused at a known location relative to the imaging system screen. Each focused applicator's lens is joined to an ultrasound coupling cylinder filled with water. Each coupling cylinder is lined with thin plastic film at the skin. The ultrasound output power of the applicators is monitored by each applicator's control unit which includes a display of the ultrasound intensity.

To perform ultrasound stimulation, ultrasound gel is placed on the skin over the nerve area in the neck. Then the coupling cylinders and imaging transducer are placed against the gel, then the DECIMA position is fixed in place by a support arm.

02

Conditions studied

  • Diabetes Mellitus, Type 2
03

In context

Diabetes Mellitus, Type 2

9,590 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,332 are open to participants now.

This study's planned enrollment of 10 is below the median of 81 across 7,713 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

This is the only study on the registry with Aucta Technologies, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written informed consent prior to any of the screening procedures
  • Willingness to comply with all study procedures and available for the duration of the study
  • Male or female age between 21 and 60 years old, inclusive
  • Diabetes Mellitus Type 2 for at least 1 year

Exclusion criteria

Exclusion Criteria:

  • HbA1c greater than 10.5%
  • Medical treatment regimen with insulin
  • Medical treatment with antiinflammatory drugs such as Disease-Modifying Antirheumatic Drugs (DMARDs), i.e. Methotrexate and Cytokine-inhibitors, e.g. Adalimumab, and Etanercept.
  • Clinically significant neuropathy in the opinion of the investigator or as documented in the subject's medical history
  • Abundant fat tissue in neck, as evidenced by a neck circumference of more than 20''
  • Clinically significant surgical procedure(s) or skin lesion(s) in neck that would affect subject safety or placement of device
  • Prior vagotomy
  • History of clinically significant vasovagal syncope or presyncope
  • Use of electrically active implanted medical device
  • History of heat stroke or any heat intolerance that is deemed clinically significant in the opinion of the investigator
  • History of renal dysfunction or a glomerulonephropathy defined as either nephritic or nephrotic syndrome, including estimated glomerular filtration rate of \<30 mL/min
  • Clinically significant cardiovascular condition or problem that in the opinion of the investigator would interfere with the study data or affect patient safety (e.g. uncontrolled hypertension, congestive heart failure, or documented evidence of prior coronary artery disease).
  • Pregnancy or plans to become pregnant while participating in the study, as determined by urine pregnancy test conducted at the screening visit for women of childbearing potential. A woman of childbearing potential is defined as a premenopausal female capable of becoming pregnant. This includes women on oral, injectable, or mechanical contraception; women who are single; women whose husbands have been vasectomized or whose husbands have received or are utilizing mechanical contraceptive devices.
  • Uncontrolled asthma or obstructive lung disease.
  • History of sepsis
  • Significant cardiac rhythm disturbances in the opinion of the investigator based on an ECG.
  • GI surgery that could have lacerated any branch of the vagus nerve, i.e. cholecystectomy, gastrectomy, pancreatic surgery, etc.
  • Other conditions that could impair the patient's ability to participate in the study according to the investigator's opinion.
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
10 participants (estimated)

Study arms

  • Sham comparator
    Sham vs Active Stimulation Positions

    Adults with Diabetes Mellitus Type 2 (DMT2) will be recruited and randomized to active uVNS or sham across two sessions according to a 2x2 crossover design. Sham uVNS will be delivered with the same stimulation parameters as active uVNS, but will be targeted to the left sternocleidomastoid muscle \~2 cm away from the vagus nerve.

    Device: Ultrasound Vagus Nerve Stimulation (DECIMA)

  • Active comparator
    Active uVNS

    Active stimulations will be targeted with the ultrasound beam of the DECIMA device .Active uVNS will be delivered to the left cervical vagus nerve following the OGTT through the 60-min time point.

    Device: Ultrasound Vagus Nerve Stimulation (DECIMA)

Interventions

  • DeviceUltrasound Vagus Nerve Stimulation (DECIMA)

    This is a single-site, double-blind, randomized, prospective, sham-controlled, crossover early feasibility study to determine whether ultrasound Vagus Nerve Stimulation (uVNS) inhibits postprandial hyperglycemia in humans.

06

What researchers measure

Primary outcomes

  1. Change in blood glucose Area Under the Curve (AUC, mg/dL ● hours) from baseline to 3 hours after an Oral Glucose Tolerance Test (OGTT) with Ultrasonic Vagus Nervous Stimulation (uVNS).hyperglycemia

    The DECIMA device comprises an array of two focused ultra-sound applicators arranged with overlapping foci to deliver acoustic energy to a known focal depth within tissue.

    Time frame: Change from baseline in the 3-hour mean glucose AUC following an OGTT

Secondary outcomes

  1. Change in whole blood lipospolysaccharide-induced TNF-Alpha (pg/mL) production from base line to 4 hours post stimulation.

    Inhibits postprandial hyperglycemia in patients with Diabetes Mellitus Type 2 via a temperature-medicated mechanism.

    Time frame: Change in mean Whole Blood Lipopolysaccharide-Induced TNF production from baseline to four (4) hours post-stimulation

07

Study locations

1 site
  • Cognitive Clinical Trials, LLC
    Scottsdale, Arizona 85258, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2019 (actual). Primary completion is estimated for Jul 2022, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2019
First posted
Sep 19, 2019
StartActual
Aug 1, 2019
Primary completionEst.
Jul 2022
CompletionEst.
Jul 2022
Last update
Aug 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04094649
Lead sponsor
Aucta Technologies, Inc.
Collaborators
STATKING Clinical Services
Responsible party
Sponsor
First posted
Sep 19, 2019
Start date
Aug 1, 2019
Primary completion
Jul 2022 (estimated)
Completion
Jul 2022 (estimated)
Last update
Aug 20, 2021

Study contacts

Albert Tejada, MD, PI
principal investigator · Synexus

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion